Liver Cirrhosis Network Cohort Study (NCT05740358)
🩺 Plain-English Summary (8th-Grade Level)
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (22 items).
Location: University of California San Diego NAFLD Research Center — La Jolla, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known and documented prior or current hepatocellular carcinoma (HCC) or cholangiocarcinoma
- Known transjugular intrahepatic portosystemic shunt (TIPS), balloon retrograde transvenous obliteration (BRTO) or porto-systemic shunt surgery regardless of time of occurrence
- Known prior solid organ transplant or bone marrow transplant
- Current participation in active medication treatment trials at the time of consent for LCN Cohort Study
- Prisoners or individuals with more than 180 days incarceration pending due to difficulty with visits
- Bariatric surgery in the last 180 days prior to consent
- Known history of fontan procedure-associated liver disease (FALD)
- Known current medical or psychiatric conditions which, in the opinion of the investigator, would make the participant unsuitable for the study or interfere with or prevent follow-up per protocol
- Current liver-unrelated end-stage organ failures (Dialysis, stage 3-4 congestive heart failure (CHF), current chronic obstructive pulmonary disease (COPD) on home oxygen, current known active malignancy besides non-melanomatous skin cancer or carcinoma in situ)
- Documented history of acute alcohol-associated hepatitis (according to NIAAA criteria as described in the MOP) in the 180 days prior to consent
- Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (14 Sites)
- University of California San Diego NAFLD Research Center — La Jolla, California
- Keck Medical Center of USC — Los Angeles, California
- LAC + USC Medical Center — Los Angeles, California
- UCSF/Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- UCSF Medical Center — San Francisco, California
- University of Miami Health System — Miami, Florida
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- New York Presbyterian/Weill Cornell — New York, New York
- Columbia University Iriving School of Medicine — New York, New York
- Duke Liver Center — Durham, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Central Virginia Veterans Healthcare System — Richmond, Virginia
- Virginia Commonwealth University — Richmond, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.